Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study

Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study

Rituximab (RTX) has been reported to effectively maintain remission in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). In this multicenter study involving 57 patients who achieved remission after 24 weeks, we evaluated the effectiveness of RTX in maintaining remission in patients w...

Full description

Saved in:
Bibliographic Details
Main Authors: Chie Ogita, Kazuteru Noguchi, Jiro Takeuchi, Naoto Azuma, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Masatoshi Kadoya, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Yutaka Kawahito, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Kiyoshi Matsui
Format: Article
Language:English
Published: Taylor & Francis Group 2025-01-01
Series:Immunological Medicine
Subjects:
Anti-neutrophil cytoplasmic antibody-associated vasculitis
induction phase of remission
maintenance phase of remission
regular administration
rituximab
Online Access:https://www.tandfonline.com/doi/10.1080/25785826.2024.2448912
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items